论文部分内容阅读
羟基红花黄色素A(HSYA)是红花的主要活性成分,具有活血化瘀的功效,临床用于心脑血管疾病的治疗。由于HSYA生物利用度低,限制了其口服制剂的开发与应用。近年来,HSYA的生物药剂学研究取得了很大进展,本文着重从HSYA理化性质、药代动力学特征、增加HSYA口服吸收的策略和制剂研究4个方面综述HSYA的研究进展,为相关研究提供参考。
Hydroxysafflor yellow A (HSYA) is the main active ingredient of safflower, has the effect of promoting blood circulation and removing blood stasis and is used clinically in the treatment of cardiovascular and cerebrovascular diseases. Because of its low bioavailability, HSYA limits its development and application of oral formulations. In recent years, great progress has been made in the biopharmaceutical research of HSYA. This review focuses on the research progress of HSYA from four aspects: the physical and chemical properties of HSYA, the characteristics of pharmacokinetics, the strategy of increasing oral absorption of HSYA and the preparation of HSYA. reference.